Page last updated: 2024-08-24

ranolazine and atrial natriuretic factor

ranolazine has been researched along with atrial natriuretic factor in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arcari, A; Arra, C; Campesan, M; Carpi, A; Cipresso, C; Condorelli, G; Coppola, C; De Lorenzo, C; Di Lisa, F; Maurea, N; Monti, MG; Piscopo, G; Quintavalle, C; Rea, D; Tocchetti, CG	1
Bonaca, MP; Braunwald, E; Jarolim, P; Morrow, DA; Murphy, SA; O'Malley, RG; Sabatine, MS; Scirica, BM	1

Trials

1 trial(s) available for ranolazine and atrial natriuretic factor

Article	Year
Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Th Journal of the American College of Cardiology, 2014, Apr-29, Volume: 63, Issue:16 Topics: Acetanilides; Acute Coronary Syndrome; Aged; Atrial Natriuretic Factor; Biomarkers; Electrocardiography; Enzyme Inhibitors; Female; Follow-Up Studies; Glycopeptides; Humans; Male; Piperazines; Prognosis; Prospective Studies; Protein Precursors; Ranolazine; Risk Factors; Sodium Channel Blockers; Thrombolytic Therapy; Time Factors; Treatment Outcome	2014

Article

Year

Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Th

Journal of the American College of Cardiology, 2014, Apr-29, Volume: 63, Issue:16

Topics: Acetanilides; Acute Coronary Syndrome; Aged; Atrial Natriuretic Factor; Biomarkers; Electrocardiography; Enzyme Inhibitors; Female; Follow-Up Studies; Glycopeptides; Humans; Male; Piperazines; Prognosis; Prospective Studies; Protein Precursors; Ranolazine; Risk Factors; Sodium Channel Blockers; Thrombolytic Therapy; Time Factors; Treatment Outcome

2014

Other Studies

1 other study(ies) available for ranolazine and atrial natriuretic factor

Article	Year
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. European journal of heart failure, 2014, Volume: 16, Issue:4 Topics: Acetanilides; Animals; Antibiotics, Antineoplastic; Atrial Natriuretic Factor; Blotting, Western; Cardiotoxicity; Connective Tissue Growth Factor; Doxorubicin; Enzyme Inhibitors; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Oxidative Stress; Piperazines; Poly(ADP-ribose) Polymerases; Ranolazine; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium; Ultrasonography; Ventricular Dysfunction, Left	2014

Article

Year

Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.

European journal of heart failure, 2014, Volume: 16, Issue:4

Topics: Acetanilides; Animals; Antibiotics, Antineoplastic; Atrial Natriuretic Factor; Blotting, Western; Cardiotoxicity; Connective Tissue Growth Factor; Doxorubicin; Enzyme Inhibitors; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Oxidative Stress; Piperazines; Poly(ADP-ribose) Polymerases; Ranolazine; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium; Ultrasonography; Ventricular Dysfunction, Left

2014